[National Trends in the Distribution of Candida Species Causing Candidemia in Japan from 2003 to 2014].

The Epidemiological Investigation Committee for Human Mycoses in Japan performed a retrospective epidemiological survey of candidemia and causative Candida species. Data from 2003 to 2014 were collected from 10 Japanese university hospitals. A total of 328,318 blood cultures were included. The prevalence of fungi in all cultures and in positive cultures were 0.58±0.09% and 4.46±0.66%, respectively. Among the results that were positive for Candida species (N=1,921), Candida albicans was the most common species (39.5%) and was followed by Candida parapsilosis (23.3%), Candida glabrata (13.2%), Candida tropicalis (7.1%), Candida krusei (3.2%), and others (13.7%). During the last 6 years, the frequency of C. albicans has significantly decreased in Japan, while that of C. glabrata has increased. Additional surveys are needed to continuously monitor the trends in the distribution of candidemia.

[1]  L. Johnson,et al.  Current trends in candidemia and species distribution among adults: Candida glabrata surpasses C. albicans in diabetic patients and abdominal sources , 2016, Mycoses.

[2]  Y. Niki,et al.  Terminal-stage prognostic analysis in candidemia. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[3]  S. Ichiyama,et al.  Predictors of Candida spp. as causative agents of catheter-related bloodstream infections. , 2014, Diagnostic microbiology and infectious disease.

[4]  J. Binongo,et al.  Distribution of Candida species isolated from blood cultures in hospitals in Osaka, Japan. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  J. Guinea.  Global trends in the distribution of Candida species causing candidemia. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  X. Nassif,et al.  Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  K. Osawa,et al.  Comparison of the clinical risk factors between Candida albicans and Candida non-albicans species for bloodstream infection , 2014, The Journal of Antibiotics.

[8]  F. Dromer,et al.  Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients , 2010, Antimicrobial Agents and Chemotherapy.

[9]  M. Pfaller,et al.  Results from the ARTEMIS DISK Global AntifungalSurveillance Study: a 6.5-Year Analysis of Susceptibilitiesof Candida and Other Yeast Species to Fluconazole andVoriconazole by Standardized Disk Diffusion Testing , 2005, Journal of Clinical Microbiology.

[10]  S. Fridkin.  Candidemia is costly--plain and simple. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Ichiyama,et al.  National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. , 2004, The Journal of antimicrobial chemotherapy.

[12]  Shane Gillespie,et al.  Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Pfaller,et al.  Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000 , 2002, Journal of Clinical Microbiology.